Gemcitabine, a novel nucleoside analogue that is activated by deoxycytidine kinase (dCK), has shown promising results in solid tumors such as nonsmall cell lung cancer and in pancreatic and ovarian cancers [10–12]. This evidence concerns the gene DCK and ovarian carcinoma.